TALPHERA, INC. (TLPH): Nasdaq/NYSE listing notice — AcelRx receives Nasdaq deficiency notice for bid price below $1.00 per share

TALPHERA, INC.

Notice dated April 26, 2023; requires minimum $1.00 bid price for continued listing on Nasdaq Global Market.
Company has 180 calendar days (until October 23, 2023) to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, AcelRx may seek an additional 180-day period if it meets other Nasdaq Capital Market listing standards.
Company states it will monitor bid price and evaluate options, including reverse stock split to cure deficiency.
Nasdaq has not yet initiated delisting; listing remains unchanged at this time.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TALPHERA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

April 26, 2023, AcelRx Pharmaceuticals, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecuti

View on SEC.gov

Browse all listing & compliance notices →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-011613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.